AbbVie Inc. (ABBV): A Bull Case Theory
We came across a bullish thesis on AbbVie Inc. (ABBV) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we will summarize the bulls’ thesis on ABBV. AbbVie Inc.
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lee Munder Capital Group Lee Munder | 167,256 | $29,721,392 | -3% | 1.82% |
| 2. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 27,728 | $4,927,300 | +1% | 1.84% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | Officer | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | Officer | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | Officer | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | Officer | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | Officer | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $172.24 | 1,800 | 6,983 | 2024-12-16 | Filing | ||
| $186.52 | 66,500 | 446,599 | 2024-08-05 | Filing | ||
| $175.00 | 282,845 | 513,099 | 2024-07-17 | Filing | ||
| $176.30 | 21,082 | 55,903 | 2024-03-20 | Filing | ||
| $178.69 | 27,740 | 60,941 | 2024-03-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 160,398,281 | $24,856,921,606 | 0.54% | |
| 2. | 143,182,709 | $22,189,024,406 | 0.56% | |
| 3. | 78,200,866 | $12,118,788,204 | 0.58% | |
| 4. | 51,818,311 | $8,030,283,833 | 0.85% | |
| 5. | 44,988,183 | $6,971,795,864 | 1.56% |
News See All
Louis Navellier's Top 15 Long-Term Stock Picks
Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to stock selection and his long-standing track record in the investment industry...
10 Best Dividend Kings Stocks to Invest in Now
Investing in dividend stocks has been a focal point for investors for several years. The attractive income generated from these stocks motivates many to invest.
Top 20 Dividend Stocks of 2024
Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% in the past week.
13 Best Pharma Dividend Stocks To Buy In 2024
The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower deal values, reflecting a shift toward smaller, more strategic transactions.
Long-Term Stock Portfolio: Best Stocks for 10 Years
To select stocks with long-term growth potential, investors should focus on fundamental analysis, evaluating financial health through earnings history, revenue growth, and profit margins.
10 Best Dividend Growth Stocks to Buy and Hold in 2025
Dividend stocks had a challenging year in 2024 as investor interest largely shifted toward technology stocks.
AbbVie (ABBV) Benefitted from Top-Line Growth From Its Immunosuppressive Drugs
Polaris Capital Management, an investment management company, released its third quarter 2024 investor letter. A copy of the same can be downloaded here.
10 Best Stocks to Buy and Hold For 3 Years
On December 12, Tom Lee, Fundstrat Global Advisors managing partner and head of research, joined CNBC's 'Closing Bell' to discuss his playbook for 2025.
10 Dividend Stocks For Steady Income
Generating income has consistently been a primary goal for investors. To achieve this, they often opt for investments that provide steady and reliable returns over time.
Billionaire Hedge Funds
